Annex Advisory Services LLC Purchases 2,731 Shares of AbbVie Inc. $ABBV

Annex Advisory Services LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,241 shares of the company’s stock after acquiring an additional 2,731 shares during the quarter. Annex Advisory Services LLC’s holdings in AbbVie were worth $13,717,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Ellenbecker Investment Group raised its stake in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA boosted its stake in AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC grew its holdings in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the period. Willner & Heller LLC raised its position in shares of AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares during the last quarter. Finally, Hobart Private Capital LLC raised its position in shares of AbbVie by 4.4% during the 3rd quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after acquiring an additional 48 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ABBV shares. UBS Group raised their target price on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Evercore ISI lifted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Trading Up 0.4%

NYSE ABBV opened at $230.95 on Tuesday. The company has a market cap of $408.18 billion, a PE ratio of 174.96, a PEG ratio of 1.31 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a 50 day moving average of $226.70 and a 200-day moving average of $212.99.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the company earned $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.